PTC Therapeutics (PTCT) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings or view top-rated stocks.

11 brokers have issued twelve-month price targets for PTC Therapeutics' shares. Their PTCT share price forecasts range from $37.00 to $66.00. On average, they anticipate the company's stock price to reach $52.93 in the next year. This suggests a possible upside of 24.1% from the stock's current price.
View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts.

PTC Therapeutics' stock was trading at $38.17 on January 1st, 2023. Since then, PTCT stock has increased by 11.8% and is now trading at $42.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PTCT earnings forecast.

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Thursday, April, 27th. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.64) by $0.24. The biopharmaceutical company earned $220.38 million during the quarter, compared to analyst estimates of $200.48 million. The firm's revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.78) EPS.

ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Direxion mRNA ETF (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dynamic Biotechnology & Genome ETF (PBE), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX) and Invesco DWA Healthcare Momentum ETF (PTH).

PTC Therapeutics updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $866.89 million.

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.56%), Wellington Management Group LLP (9.43%), Armistice Capital LLC (3.94%), State Street Corp (3.92%), Price T Rowe Associates Inc. MD (2.32%) and Macquarie Group Ltd. (2.21%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTCT stock can currently be purchased for approximately $42.66.

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.16 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($7.89) on an earnings per share basis.

The company employs 1,410 workers across the globe.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.